Buy Imatinib Mesylate 100 mg online, Buy Gleevec online.

Imacent (Imatinib Mesylate) 100 mg by incepta pharma is used to treat Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors(GIST).

Imacent is the alternative & generic version of Gleevec by Novartis. Imacent is manufactured by Incepta Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.

Therapeutic Class

Targeted Cancer Therapy

Pharmacology

Imatinib, is a tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML).

It blocks proliferation and induces apoptosis in BCR-ABL positive cell lines, as well as fresh leukaemic cells from Philadelphia chromosome positive CML.

Imatinib also inhibits receptor kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, PDGF- and SCF-mediated cellular events.

Dosage

Oral (Adult)-

Dermatofibrosarcoma protuberans: 400 mg bid.

Chronic myeloid leukaemia: Chronic phase: 400 mg daily, increased to 600 mg daily or 400 mg bid. Blast crisis or accelerated phase: 600 mg daily, increased to 400 mg bid as required.

Mastocytosis: 400 mg daily. Start with 100 mg daily if there is associated eosinophilia, may increase to 400 mg if response is insufficient.

Unresectable, metastatic malignant gastrointestinal stromal tumours: 400 mg daily, may increase up to 400 mg bid.

Myelodysplastic disease: 400 mg daily.

Acute lymphoblastic leukaemia, Monotherapy in relapsed or refractory acute lymphoblastic leukaemia: 600 mg daily with induction, consolidation or maintenance chemotherapy.

Hypereosinophilic syndrome: 400 mg daily. Start with 100 mg daily in patients with FIP1L1-PDGF receptor-α fusion kinase, may increase to 400 mg if response is inadequate.

Oral (Child)-

Chronic myeloid leukaemia: 340 mg/m² daily. Max: 800 mg. May be given once daily or divided into morning and evening doses. May be increased to 570 mg/m² daily in childn w/ disease progression,

unsatisfactory haematological response at least 3 mth of treatment, failed to achieve cytogenic response after 12 mth of treatment or loss a previously achieved haematological or cytogenic response.

Acute lymphoblastic leukaemia, Monotherapy in relapsed or refractory acute lymphoblastic leukaemia: 340 mg/m² daily. Max: 600 mg.

Administration

Should be taken with food.

Interaction

Imatinib, Increased serum levels with CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels with CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum

levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.

Contraindications

Hypersensitivity. Lactation.

Side Effects

Imatinib, GI disturbances and bleeding, myelosuppression, superficial oedema, myalgia, arthralgia, muscle cramps, fatigue, rhabdomyolysis, rashes, pruritus, headache, dizziness, taste disturbances, anorexia, paraesthesia, insomnia, eye disorders or visual disturbances, epistaxis, cough, dyspnoea, dry skin, alopecia, night sweats, pyrexia,

weakness, rigors, haemorrhages, growth retardation in childn, CHF, palpitations, tachycardia, arrhythmias, angina pectoris and MI. Rarely, serious and severe skin disorders (e.g. erythema multiforme, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, exfoliative dermatitis and bullous eruptions); aseptic necrosis of bone, ulceration.

Rarely, serious and severe skin disorders (e.g. erythema multiforme, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, exfoliative dermatitis and bullous eruptions); aseptic necrosis of bone, ulceration.

Rarely, serious and severe skin disorders (e.g. erythema multiforme, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, exfoliative dermatitis and bullous eruptions);

Pregnancy & Lactation

Category D: Imatinib, There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Precautions & Warnings

Patient with cardiac disease or increased risk for CHF. Renal and hepatic impairment. Pregnancy.

Use in Special Populations

Patients on potent CYP3A4 inducers: Increase dose by 50% and carefully monitor clinical response.

Severe Hepatic Impairment: Reduce dose by 25%.

Overdose Effects

Symptoms: Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, headache, pyrexia, decreased appetite, weakness, myalgia, GI pain, decreased neutrophil count, increased creatine phosphokinase, bilirubin and transaminases.

Management: Supportive and symptomatic treatment.

Storage Conditions

Store below 30° C. Protect from moisture.